Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20050074843A1
SERIAL NO

10633699

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ROCHE GLYCART AGWAGISTRASSE 18 SCHLIEREN-ZURICH CH-8952

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bailey, James E Zurich, CH 30 1601
Jean-Mairet, Joel Zurich, CH 9 1199
Umana, Pablo Zurich, CH 247 5409

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation